https://www.avient.com/sites/default/files/2021-05/avnt-first-quarter-2021-earnings-presentation.pdf
Microsoft PowerPoint - Avient Q1 2021 Earnings - Final (For Print)
AVIENT CORPORATION
F I R S T Q U A R T E R 2 0 2 1 R E S U LT S
(NYSE: AVNT)
A P R I L 3 0 , 2 0 2 1
DISCLAIMER
2
Forward-Looking Statements
In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
$86
$123
$0.53
$0.89
Q1 2021 – ORGANIC PERFORMANCE
3
Sales Adjusted Operating Income
$991
$1,162
+ 17%
+ 43% + 68%
(1) (1) (1)
Q1 2021 SEGMENT PERFORMANCE
4
CAI
$536
$609
($ in millions)
SEM Distribution
$64
$89
+14%
+39%
$290
$363
$19
$24
+25%
+26%
$185
$217
$22
$34
+17%
+55%
SPECIALTY EBITDA MARGIN EXPANSION
5
CAI
(1) 2018-2020 financial information is pro forma to include a full year of Clariant Masterbatch business acquisition
15.3% 15.2%
16.2%
19.1%
2018 2019 2020 Q1 2021
14.8% 15.2%
17.6%
19.4%
2018 2019 2020 Q1 2021
SEM
• Continued portfolio transformation to
high-growth end markets and
sustainable solutions
• Clariant Masterbatch synergy realization
• Investments in composites and outdoor
high performance applications drive
growth and mix improvements
CAI EBITDA MARGIN EXPANSION
6
Legacy CAI
18.9% 18.9%
21.0%
2019 2020 Q1 2021
Legacy
11.9%
13.8%
17.4%
2019 2020 Q1 2021
• Early synergy capture translating to
the bottom line
• Positive mix with growth in healthcare,
consumer and packaging end-markets
• World-class vitality index of 36%
represents sales from products
introduced in the last five years.
Develop and implement solutions to end plastic
waste while supporting AEPW $1.5B
investment in key initiatives.
2030 SUSTAINABILITY TARGETS
15
PEER COMPARISONS
16
$442
$457
$560
$1.74
$1.93
$2.80
FULL YEAR 2019 – 2021 ORGANIC GROWTH
17
Sales Adjusted EBITDA
$3,981
$3,783
$4,300
+ 8%
(1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition
(1)(1)
+ 27% + 61%
As a specialty formulator, we don’t
require significant capital
investment, as compared to the
base resin raw material suppliers
we purchase from.